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Background: Estrogen acts on the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons are
located, to elicit vasodepressor effects via an estrogen receptor (ER)β-dependent mechanism. We investigated in
the present study nontranscriptional mechanism on cardiovascular effects following activation of ERβ in the RVLM,
and delineated the involvement of phosphatidylinositol 3-kinase (PI3K)/serine/threonine kinase (Akt) signaling
pathway in the effects.
Methods: In male Sprague–Dawley rats maintained under propofol anesthesia, changes in arterial pressure, heart
rate and sympathetic neurogenic vasomotor tone were examined after microinjection bilaterally into RVLM of 17β-
estradiol (E2β) or a selective ERα or ERβ agonist. Involvement of ER subtypes and PI3K/Akt signaling pathway in the
induced cardiovascular effects were studied using pharmacological tools of antagonists or inhibitors, gene
manipulation with antisense oligonucleotide (ASON) or adenovirus-mediated gene transfection.
Results: Similar to E2β (1 pmol), microinjection of ERβ agonist, diarylpropionitrile (DPN, 1, 2 or 5 pmol), into
bilateral RVLM evoked dose-dependent hypotension and reduction in sympathetic neurogenic vasomotor tone.
These vasodepressive effects of DPN (2 pmol) were inhibited by ERβ antagonist, R,R-tetrahydrochrysene (50 pmol),
ASON against ERβ mRNA (250 pmol), PI3K inhibitor LY294002 (5 pmol), or Akt inhibitor (250 pmol), but not by ERα
inhibitor, methyl-piperidino-pyrazole (1 nmol), or transcription inhibitor, actinomycin D (5 or 10 nmol). Gene transfer
by microinjection into bilateral RVLM of adenovirus encoding phosphatase and tensin homologues deleted on
chromosome 10 (5 × 108 pfu) reversed the vasodepressive effects of DPN.
Conclusions: Our results indicate that vasodepressive effects following activation of ERβ in RVLM are mediated by
nongenomic activation of PI3K/Akt signaling pathway. This study provides new insight in the intracellular signaling
cascades involved in central vasodepressive functions of estrogen.
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The primary female sex steroid, estrogen has long been
recognized as an important hormone in a wide variety of
physiological processes, including the development,
growth, metabolism, reproduction, cardiovascular and
sexual function in both humans and animals [1]. Most of
these biological actions appear to be mediated through
the estrogen receptor (ER) subtypes, ERα and ERβ, a
member of the nuclear receptor superfamily that func-
tion as ligand-activated transcriptional factors [2,3].
Upon binding to its ligand, ER forms homodimers or het-
erodimers between the subtypes, and bind to a specific
DNA sequence located in the promoter region of target
genes where it regulates gene expression through direct
interactions with DNA or other transcriptional machin-
ery proteins [2,3].
It is now recognized that not all biological effects of es-
trogen are mediated by this well-established transcrip-
tional mode of action. Recent studies have shown that a
subpopulation of the traditional nuclear ERs is localized
at the cell membrane and they mediate many of the rapid
signaling actions of estrogen via nontranscriptional
mechanisms [3-7]. In the heart and peripheral blood ves-
sels, nongenomic mechanisms underlie estrogen-induced
rapid arterial vasodilation [5,6], inhibition of atheroscler-
otic lesions [5,8], cardioprotective effect following
trauma-hemorrhage [7], and amelioration of ischemia/
reperfusion-induced myocardial injury [9]. These nonge-
nomic actions of estrogen are thought to be mediated via
activation of the phosphatidylinositol 3-kinase (PI3K) [5-
7] and serine/threonine kinase Akt (Akt) [5,7] signaling
cascades following direct activation by the hormone of
the cellular membrane rather than intracellular receptors
[4,5,7,10].
Besides their well-known peripheral roles in cardiovas-
cular functions, accumulating evidence indicates that es-
trogen in the brain also participates in the regulation of
cardiovascular functions [11-18]. Central administration
of estrogen effectively augments sympathetic nerve activ-
ity resulting in the increase in systemic arterial pressure
(SAP) in female rats [11]. In estrogen-replaced ovariecto-
mized female rats [16], but not in male rats [15], periph-
eral injection of estrogen decreases baseline sympathetic
outflow and SAP that are antagonized by central injection
of the ER antagonist [15,16]. In addition, immunohisto-
chemical [19,20] and in situ hybridization studies [19,20]
have demonstrated the distribution of both ER mRNA
and protein in neurons of the rostral ventrolateral me-
dulla (RVLM), where the sympathetic premotor neurons
are located [21]. These anatomical findings suggest this
nucleus as a candidate substrate to subserve the central
cardiovascular regulatory actions of estrogen. In this re-
gard, microinjection of estrogen into the RVLM causes a
rapid suppression in autonomic vasomotor tone and SAP[13,14,17]. Moreover, our recent study [17] reported that
activation of ERβ in the RVLM mediates the reduction in
autonomic functions produced by estrogen. Contribu-
tions of nongenomic mechanisms and its downstream
signaling pathways underlying the central cardiovascular
effects of ERβ activation in the RVLM, however, are unex-
plored. The present study was undertaken to assess the
hypothesis that ERβ activation in the RVLM participates
in neural regulation of cardiovascular functions via non-
genomic mechanisms that entail activation of PI3K/Akt
signaling pathways. Our results demonstrated that estro-
gen in the RVLM evoked vasodepressive effects through
activation of ERβ, but not ERα receptors, and nonge-
nomic activation of PI3K/Akt signaling pathway.
Methods
Animals
All animal care and experimental protocols were
approved by Institutional Animal Care and Use Commit-
tee of Tajen University, and were in accordance with the
Guide for the Care and Use of Laboratory Animals pub-
lished by the U.S. National Institutes of Health (NIH
Publication No. 85–23, revised 1996). Adult male Spra-
gue–Dawley rats weighing 250–300 g (n = 142) were
purchased from the Experimental Animal Center of the
National Science Council and BioLASCO, Taiwan, Re-
public of China. They were housed under conditions of
constant temperature (23 ± 0.5 °C) and humidity
(50 ± 5 %) with a standard 12 h light–dark cycle (08:00–
20:00) and unrestricted access to standard laboratory rat
chow (Purina) and tap water. All animals were allowed
to acclimatize for at least 7 days before experimental
manipulations. All efforts were made to reduce the num-
bers of animals used and to minimize animal suffering at
each stage of the experiment.
General animal preparation
The preparatory surgery that included intubation of the
trachea and cannulation of the femoral artery and both
femoral veins was performed under an induction dose of
pentobarbital sodium (50 mg/kg, i.p.) [17,22]. During
recording session, the anesthesia was maintained by con-
tinuous intravenous infusion of propofol (Zeneca Phar-
maceuticals, Macclesfield, UK) at 20–25 mg/kg/h, which
provided satisfactory anesthetic maintenance while pre-
serving the capacity of neural control of cardiovascular
functions [23]. Pulsatile and mean SAP (MSAP), as well
as heart rate (HR), was continuously displayed on a poly-
graph (Gould RS3400, Valley View, OH, USA) via a pres-
sure transducer (BD P23XL, Franklin Lakes, NJ, USA).
Animals were ventilated mechanically by the use of a
small rodent ventilator (Harvard 683, South Natik, MA,
USA) to maintain an end-tidal CO2 within 4.0-4.5 %, as
monitored by a capnograph (Datex Normocap, Helsinki,
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possible confounding cardiovascular changes secondary
to respiratory perturbation. The head of the animal was
thereafter fixed to a stereotaxic head holder (Kopf 1430,
Tujunga, CA, USA), and the rest of the body was placed
on a thermostatically controlled pad to maintain rectal
temperature of 37 ± 0.5 °C. All data were collected from
animals with a steady baseline MSAP above 90 mmHg
at the beginning of the recording period.
Recording and power spectral analysis of SAP signals
The waveform signals of SAP recorded from the femoral
artery were simultaneously subject to online power spec-
tral analysis as detailed previously [23-25]. The SAP sig-
nals were resampled at 256 Hz by an eight-point
averaging algorithm, and analyzed was truncated into
16-s (2,048 points) time segments with 50 % overlap. A
Hamming window in the time domain was used to de-
cline the leakage effect [24,26]. Power spectral density of
different frequency components of SAP signals was com-
puted using a fast Fourier transform. We were particu-
larly interested in the very low-frequency (0–0.25 Hz)
and low-frequency (0.25-0.8 Hz) components of the SAP
spectrum. These frequency components of SAP signals
were reported to take origin from the RVLM [25] and
their power density reflect the prevailing sympathetic
neurogenic vasomotor tone [17,22,23,25,27]. The power
densities of these two spectral components were dis-
played during the experiment, alongside SAP, MSAP and
HR, in an online and real-time manner.
Microinjection of test agents into the RVLM
Similar to the procedures described previously [17,27],
microinjection bilaterally of test agents into the function-
ally identified RVLM sites was performed stereotaxically
and sequentially with a glass micropipette (external tip
diameter: 50–80 μm) connected to a 0.5-μL Hamilton
microsyringe (Reno, NV, USA). The stereotaxic coordi-
nates for the RVLM were 4.5 to 5.0 mm posterior to
lambda, 1.8 to 2.1 mm lateral to midline, and 8.0 to
8.5 mm below the dorsal surface of the cerebellum. These
coordinates were selected to cover the ventrolateral me-
dulla in which both ER mRNA [19] and protein [20,28]
are distributed, and where functionally identified sympa-
thetic premotor neurons are located [21]. At the begin-
ning of each experiment, the functional location of
RVLM neurons on either side was established by moni-
toring a transient pressor response (15–25 mmHg) after
microinjection of L-glutamate (1 nmol, Sigma–Aldrich).
Subsequent microinjections of test agents were delivered
to the identified pressor loci. The test agents used in this
study included 17β-estradiol-3-sulphate sodium (E2β;
Sigma–Aldrich, St. Louis, MO, USA); a selective ERα
agonist, 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1 H-pyrazole(PPT; Tocris Cookson Inc., Bristol, UK); a selective ERβ
agonist, diarylpropionitrile (DPN; Tocris Cookson); a
nonspecific ER antagonist, ICI 182780 (Tocris Cookson);
a selective ERα antagonist, methyl-piperidino-pyrazole
(MPP; Tocris Cookson); a selective ERβ antagonist,
R,R-tetrahydrochrysene (R,R-THC; Tocris Cookson); a
transcription inhibitor, actinomycin D (AMD; Tocris
Cookson); a PI3K inhibitor, LY294002 (Calbiochem, San
Diego, CA, USA); an Akt inhibitor (Calbiochem); an anti-
sense oligonucleotide (ASON) against the rat ERα or
ERβ mRNA (Quality Systems, Taipei, Taiwan) or the
scrambled (SCR) ERα or ERβ oligonucleotide (Quality
Systems). For ERα mRNA, the ASON sequence was 5’-
CATGGTCATGGTCAG-3’ and the SCR sequence was
5’-ATCGTGGATCGTGAC-3’ [29]. For ERβ mRNA, the
ASON sequence was 5’-GAATGTCATAGCTGA-3’ and
the SCR sequence was 5’-AAGGTTATCGCAAGT-3’
[29]. A total volume of 50 nl was microinjected to each
side of RVLM. The dose of test agents and treatment
regimen were adopted from our preliminary experiments
and previous studies [17,30] that used the same test
agents for the same purpose as in this study. The dose of
each antagonist or inhibitor used in this study has been
shown in our pilot studies to significantly inhibit cardio-
vascular responses induced by its specific ligand or en-
zyme. All test agents were freshly dissolved in artificial
cerebrospinal fluid (aCSF) at pH 7.4, except for ICI
182780, AMD and LY294002, which used 5 % dimethyl
sulfoxide (DMSO) as the solvent. The composition of
aCSF was (in mM): NaCl 117, NaHCO3 25, glucose 11,
KCl 4.7, CaCl2 2.5, MgCl2 1.2, and NaH2PO4 1.2. Control
experiments showed that these vehicles had no signifi-
cant effect on baseline MSAP or HR during the 120 min
observation period. To avoid confounding effects of drug
interactions, each animal received only one treatment of
synthetic estrogen, selective ERα, ERβ agonist or vehicle,
given alone or in combination with one test agent. Pre-
treatment with microinjection into the bilateral RVLM of
AMD, or ERα or ERβ ASON or SCR, were carried out
1 h or 24 h respectively, prior to DPN application.
Construction and purification of recombinant AdPTEN
To construct adenovirus encoding phosphatase and ten-
sin homologues deleted on chromosome 10 (AdPTEN)
or green fluorescence protein (AdGFP), human PTEN
complementary DNA or GFP was subcloned into the
adenovirus transfer vector pCA13 (Microbix, Toronto,
Ontario, Canada) to yield the pCA13-PTEN or pCA13-
GFP fusion protein. Subsequently, recombinant adeno-
virus was generated by cotransfection of pCA13-PTEN
or pCA13-GFP with the pJM17 vector (Microbix, To-
ronto, Ontario, Canada), a plasmid containing the
adenoviral genome, into 293 cells [27]. The adenoviruses
were purified by CsCl ultracentrifugation and desalted
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adenoviruses were determined by measuring optical
density at 260 nm and plaque-forming assays using 293
cells. AdGFP served as the control viruses [27].
Adenovirus-mediated PTEN gene transfer into the RVLM
The gene transfer of PTEN into the RVLM was per-
formed by microinjection bilaterally into the nucleus of
AdGFP or AdPTEN 7 days prior to DPN administration.
An adenoviral suspension containing 5 × 108 plaque-
forming units (pfu)/100 nl was administered into each
injection site over 10–15 min using a glass micropipette
[27]. The coordinates used are the same for microinjec-
tion of the test agents. Following the microinjection, the
muscle layers covering the fourth ventricle were sutured.
Body temperature was maintained at 37 °C with heating
pads until the animals had recovered from surgery. The
rats were allowed to recover in their home cages with
free access to food and water. Only animals that showed
progressive weight gain after the gene transfer were used
in subsequent experiments.
Protein extraction and Western blot analysis
For quantitative analysis of PTEN protein expression in
the RVLM, the ventrolateral medulla was rapidly
removed and placed on dry ice. Tissues on both sides at
the level of RVLM (0.5 to 1.5 mm rostral to the obex)
that contained the injection sites were collected, and the
same medullary samples thus obtained from 4–6 rats
under the same experimental condition were pooled and
stored at −80 °C until further analysis. Western blot ana-
lysis [27,31,32] was carried out on protein extraction
from the RVLM for PTEN or β-tubulin. The primary
antiserum used included rabbit polyclonal antiserum
against PTEN (1:1000; Upstate Biotechnology, Lake Pla-
cid, NY, USA) or β-tubulin (1:10000; Sigma–Aldrich).
This was followed by incubation with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:10000;
Jackson Immunoresearch Laboratories, West Grove, PA,
USA). Specific antibody–antigen complex was detected
using an enhanced chemiluminescence Western blot de-
tection system (Perkin–Elmer Life Sciences, Boston, MA,
USA). The amount of detected protein was quantified by
Photo-Print Plus software (ETS Vilber-Lourmat, France)
and was expressed as fold change relative to basal PTEN
protein level. β-tubulin served as an internal control to
demonstrate equal loading of the proteins.
Immunohistochemical staining
The procedures of immunohistochemical staining were
described previously [33]. At day 7 after the gene trans-
fer, rats were deeply anesthetized with pentobarbital so-
dium (100 mg/kg, i.p.) and perfused transcardially with
warm heparinized saline, followed by ice-cold 4 %paraformaldehyde in 0.1 M PBS (pH 7.4). The brain
stem was rapidly removed and post-fixed in the latter
solution overnight at 4 °C. 35-μm coronal sections of the
rostral medulla oblongata were cut using a cryostat.
After pre-absorption in gelatin (0.375 %), normal horse
serum (3 %) and triton-X 100 (0.2 %) in PBS, the sec-
tions were incubated with a rabbit polyclonal antibody
against PTEN (1:1000; Wako). After incubation in bioti-
nylated horse anti-mouse IgG (1:200; Jackson ImmunoR-
esearch), the sections were rinsed in PBS and incubated
with AB complexes (Vectastain ABC elite kit, Vector La-
boratories, Burlingame, CA). This was followed by incu-
bation with a 3,3’-diaminobenzidine substrate kit f
(Vector Laboratories). Sections were rinsed in PBS and
dehydrated by passing through graded series of ethanol
and xylene. Sections were mounted and observed under
a light microscope (BX53, Olympus optical, Tokyo,
Japan).
Brain histology
At the conclusion of each experiment, the animal was
killed by an overdose of pentobarbital sodium (100 mg/
kg, i.p.), and the brain stem was removed from animals
and fixed in 30 % sucrose in 10 % formaldehyde–saline
solution for at least 72 h. Histological verification of the
location of microinjection sites was carried out on fro-
zen 25-μm sections stained with 1 % Neutral red
(Sigma–Aldrich).
Statistical analysis
All values are expressed as mean± SEM. For functional
experiments, the time course of the effects of various
treatments on MSAP, HR or power density of vasomotor
components of SAP spectrum were assessed using two-
way analysis of variance (ANOVA) with repeated mea-
sures for group difference. For biochemical experiments,
differences between treatment groups were assessed using
one-way ANOVA. This was followed by the Scheffé
multiple-range test for post hoc assessment of individual
means. The maximal changes in the hemodynamic para-
meters were evaluated with Student’s t-test. P < 0.05 was
considered statistically significant.
Results
Cardiovascular effects following microinjection bilaterally
into the RVLM of E2β, ERα or ERβ agonist
Compared with aCSF treatment, bilateral microinjection
of E2β (1 pmol) into the functionally identified pressor
region of RVLM resulted in significant decreases in
MSAP and power density of vasomotor components of
SAP spectrum, our experimental index for sympathetic
neurogenic vasomotor outflow [17,22,23,27,30,32], with
no apparent change in HR (Figure 1). Similar observa-
tions were found in animals that received microinjection
Figure 1 Cardiovascular effects following microinjection
bilaterally into the RVLM of E2β, ERα or ERβ agonist. Time-
course of the changes in mean systemic arterial pressure (MSAP),
heart rate (HR) and total power density of vasomotor components
(0–0.8 Hz) of systemic arterial pressure (SAP) spectrum in
anaesthetized rats that received microinjection bilaterally into the
rostral ventrolateral medulla (RVLM, at time 0) of artificial
cerebrospinal fluid (aCSF), 17β-estradiol (E2β, 1 pmol),
diarylpropionitrile (DPN, 1, 2 or 5 pmol) or 1,3,5-tris(4-
hydroxyphenyl)-4-propyl-1 H-pyrazole (PPT, 5 pmol). Values are
presented as the mean± SEM; n = 6-8 animals per experimental
group. *P< 0.05 versus aCSF group in the post hoc Scheffé multiple-
range test.
Figure 2 Effects of ER antagonist on the E2β agonist-induced
vasodepressive responses. Time-course of the changes in MSAP
and total power density of vasomotor components (0–0.8 Hz) of
SAP spectrum in anaesthetized rats that received microinjection
bilaterally into the RVLM (at time 0) of aCSF, or DPN (2 pmol) given
together with ICI 182780 (ICI, 0.25 or 0.5 pmol), R,R-THC (50 pmol),
MPP (1 nmol) or 5 % DMSO. Values are presented as the
mean± SEM; n = 6-8 animals per experimental group. *P< 0.05 versus
aCSF group and #P< 0.05 versus DPN+DMSO group in the post hoc
Scheffé multiple-range test.
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lateral RVLM. The dose-dependent vasodepressive
responses of DPN commenced approximately 30 min,
and lasted for at least 120 min postinjection. At the low
dose (2 pmol), DPN elicited vasodepressor effects that
sustained for more than 3–4 hours postinjection, which
similar duration was also observed at 1 pmol of E2β.
Microinjection bilaterally into the RVLM of a selective
ERα agonist PPT (5 pmol), on the other hand, did not
affect basal hemodynamic parameters. Microinjection ofthe same doses of DPN (2 or 5 pmol) into the ventrolat-
eral medullary areas adjacent to, but outside the confine
of RVLM, e.g., spinal trigeminal nucleus or lateral para-
gigantocellular nucleus, also elicited minimal effects on
the cardiovascular parameters (data not shown). Since
DPN at 2 pmol produced moderate hypotension and re-
duction in sympathetic vasomotor tone, this dose was
used in the subsequent experiments.
Effects of ER antagonist on the ERβ agonist-induced
vasodepressive responses
Compared with aCSF or 5 % DMSO controls, co-
administration bilaterally into the RVLM of a nonspecific
ER antagonist, ICI 182780 (0.25 or 0.5 pmol) significantly
attenuated the vasodepressive responses of DPN (2 pmol)
in a dose-dependent manner (Figure 2). At the high dose
(0.5 pmol), ICI 182780 almost completely blocked the
DPN-induced hypotension and the decrease in sympa-
thetic vasomotor tone. The vasodepressive responses
induced by DPN (2 pmol) were also completely reversed
by co-administration into the bilateral RVLM of a specific
ERβ antagonist, R,R-THC (50 pmol), but not a specific
Figure 3 Effects of ERα or ERβ ASON on the ERβ agonist-
induced vasodepressive responses. Time-course of the changes in
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tenuation was also obtained when R,R-THC (50 pmol)
was microinjected into the bilateral RVLM at 20 min
before DPN administration, whereas MPP (1 nmol) pre-
treatment was ineffective (data not shown). Microinjec-
tion bilaterally into the RVLM of ICI 182780 (0.25 or
0.5 pmol), R,R-THC (50 pmol) or MPP (1 nmol) alone,
on the other hand, had no discernible effect on baseline
MSAP, HR or power density of vasomotor components
of SAP spectrum (Table 1).
Effects of ERα or ERβ ASON on the ERβ agonist-induced
vasodepressive responses
Figure 3 shows that microinjection bilaterally of ERβ
ASON (250 pmol) into the RVLM 24 hours before DPN
(2 pmol) administration significantly attenuated the DPN-
induced hypotension and reduction in power density of
vasomotor components of SAP spectrum. Control appli-
cation of ERα ASON, ERα SCR or ERβ SCR was ineffect-
ive. The ERα ASON (250 pmol), ERα SCR (250 pmol),
ERβ ASON (250 pmol) or ERβ SCR (250 pmol), when
administered bilaterally into the RVLM alone, did not
affect the baseline MSAP, HR or power density of vaso-
motor components of SAP spectrum (Table 1).Table 1 Effects of test agents on baseline MSAP, HR and
power density of vasomotor components of SAP
spectrum in RVLM
Treatment Maximal changes in
MSAP(mmHg) HR(bpm) Power
Density(mmHg2)
aCSF +3.8 ± 0.5 +4.7 ± 0.9 +0.6 ± 0.7
ICI 182780 (0.25 pmol) +4.3 ± 0.4 +5.2 ± 0.6 +0.6 ± 0.6
ICI 182780 (0.5 pmol) +4.5 ± 0.5 +5.5 ± 0.3 +0.7 ± 0.5
R,R-THC (50 pmol) +4.6 ± 0.7 +5.7 ± 0.8 +0.8 ± 0.7
MPP (1 nmol) +5.3 ± 0.7 +5.1 ± 1.1 +0.8 ± 0.3
AMD (5 nmol) −4.2 ± 0.6 +2.4 ± 1.2 −0.6 ± 0.7
AMD (10 nmol) −4.5 ± 0.6 −3.4 ± 1.5 −0.6 ± 0.5
LY294002 (5 pmol ) +3.0 ± 0.7 −4.4 ± 1.0 +0.7 ± 0.6
Akt inhibitor (250 pmol) +2.8 ± 0.8 +4.0 ± 0.8 +0.8 ± 0.4
AdGFP (5 × 108 pfu) −4.1 ± 0.8 +5.1 ± 1.2 −0.7 ± 0.6
AdPTEN (5 × 108 pfu) −4.8 ± 1.1 +5.7 ± 1.0 −1.0 ± 0.5
ERα ASON (250 pmol) +5.5 ± 0.5 +5.5 ± 1.2 +0.6 ± 0.5
ERβ ASON (250 pmol) +5.4 ± 1.0 +4.6 ± 1.1 +0.7 ± 0.7
ERα SCR (250 pmol) +4.1 ± 0.8 +3.6 ± 1.0 +0.8 ± 0.7
ERβ SCR (250 pmol) +4.9 ± 0.7 −3.9 ± 0.6 +0.7 ± 0.5
The baseline MSAP, HR and power density of vasomotor components of SAP
spectrum were measured at 120 min, 24 h, or day 7 respectively, after
microinjection bilaterally into RVLM of other test agents, ERα or ERβ ASON or
SCR, or AdGFP or AdPTEN. All values are expressed as mean± SEM; n = 6-7
animals per experimental group. Any significant differences (P< 0.05) were not
detected between all the test agent groups and aCSF group in the
Student’s t-test.
MSAP and total power density of vasomotor components (0–0.8 Hz)
of SAP spectrum in anaesthetized rats that received microinjection
bilaterally into the RVLM (at time 0) of aCSF, or to rats pretreated
with ERα ASON (250 pmol), ERα SCR (250 pmol), ERβ ASON (250
pmol), ERβ SCR (250 pmol) or aCSF, administered into the bilateral
RVLM 24 hours before DPN (2 pmol) microinjection. Values are
presented as the mean± SEM; n = 6-7 animals per experimental
group. *P< 0.05 versus aCSF group and #P< 0.05 versus aCSF +DPN
group in the post hoc Scheffé multiple-range test.Effects of RNA synthesis inhibitor on the ERβ agonist-
induced vasodepressive responses
We further investigate the involvement of nongenomic
and/or genomic mechanisms in the DPN-induced car-
diovascular depressive responses. Compared with 5 %
DMSO controls, pretreatment with microinjection of a
transcription inhibitor, AMD (5 or 10 nmol), into the bi-
lateral RVLM 1 h prior to DPN administration (2 pmol),
did not affect hypotension and reduction in power dens-
ity of vasomotor components of SAP spectrum induced
by DPN (Figure 4). Microinjection into bilateral RVLM
of AMD (5 or 10 nmol) alone had no significant effect
on baseline MSAP, HR or power density of vasomotor
components of SAP spectrum (Table 1).Effects of PI3K inhibitor, Akt inhibitor or AdPTEN on the
ERβ agonist-induced vasodepressive responses
To decipher the role of PI3K/Akt signaling pathway in
the DPN-induced vasodepressive responses, we evaluated
the effects of PI3K inhibitor, Akt inhibitor or AdPTEN in
Figure 4 Effects of RNA synthesis inhibitor on the ERβ agonist-
induced vasodepressive responses. Time-course of the changes in
MSAP and total power density of vasomotor components (0–0.8 Hz)
of SAP spectrum in anaesthetized rats that received microinjection
bilaterally into the RVLM (at time 0) of aCSF, or to rats pretreated
with actinomycin D (AMD, 5 or 10 nmol) or 5 % DMSO,
administered into the bilateral RVLM 1 hour before DPN (2 pmol)
microinjection. Values are presented as the mean± SEM; n = 7-8
animals per experimental group. *P< 0.05 versus aCSF group in the
post hoc Scheffé multiple-range test.
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DPN. In contrast to vehicle injection, co-administration
bilaterally into the RVLM of a PI3K inhibitor, LY294002
(5 pmol), or an Akt inhibitor (250 pmol), significantly
decreased the vasodepressive responses of DPN (2 pmol)
(Figure 5A). Similar results were obtained when
LY294002 or Akt inhibitor was administered into the
bilateral RVLM 30 min before DPN microinjection
(data not shown). We also found that DPN-induced
hypotension and reduction in power density of vasomotor
components of SAP spectrum were significantly reversed
7 days after the gene transfection of AdPTEN (a total of
5 × 108 pfu) to the bilateral RVLM (Figure 5B). Micro-
injection bilaterally into the RVLM of AdPTEN resulted
in a significant increase in PTEN protein expression,
which peaked on day 7 after the gene transfer
(Figure 5C). On day 7 after the gene transfection, distri-
bution of PTEN-positive immunoreactivity was also sig-
nificantly increased in RVLM (Figure 5D). Microinjection
bilaterally into the RVLM of LY294002 (5 pmol), Akt in-
hibitor (250 pmol), AdGFP (5 × 108 pfu) or AdPTEN
(5× 108 pfu) alone had no effect on baseline MSAP, HRor power density of vasomotor components of SAP
spectrum (Table 1).
Microinjection sites
Histological verification of locations of micropipette tips
in the ventrolateral medulla confirmed that all observa-
tions were made from animals that received local admin-
istration of the test agents within the anatomic confines
of the RVLM (Figure 6). For the purpose of clarity,
Figure 6 only summarizes the location of sites where
microinjection of E2β (1 pmol) or DPN (2 pmol) exhib-
ited significant (P < 0.05) inhibitory effects on the MSAP
and power density of vasomotor components of SAP
spectrum.
Discussion
The major finding of the present study is that nontran-
scriptional activation of PI3K/Akt signaling mediates the
short-term hypotension and reduction in sympathetic
vasomotor tone induced by ERβ activation in the RVLM.
It is well established that the sympathetic premotor neu-
rons within the RVLM plays a pivotal role in the gener-
ation and maintenance of the tonic sympathetic
vasomotor outflow [21]. It is also known that spectral
vasomotor components (very low-frequency and low-
frequency) of SAP signals take origin from these RVLM
neurons [25]. In agreement with our recent observations
[17], we found in the present study that direct micro-
injection of E2β into the RVLM of male rats elicited sig-
nificant decreases in SAP and power density of the
vasomotor components of SAP signals, our experimental
index for sympathetic neurogenic vasomotor outflow
[17,22,23,27,30,32]. In addition, we found closely corre-
lated temporal profiles between the reduced power dens-
ity of the vasomotor components of SAP signals and
hypotensive effect after microinjection of E2β or ERβ
agonist into the bilateral RVLM, suggesting that estrogen
can acting directly on the RVLM neurons to reduce the
tonic sympathetic vasomotor outflow, resulting in a de-
crease of SAP. In the present study, we purposely used
male animals to avoid confounding cardiovascular
effects induced by differing levels of circulating estrogen
in female rats. Subramanian and colleagues [34] recently
demonstrated in female rats that chronic exposure to
low levels of E2β by peripheral slow-release pellets
caused significant increases in superoxide production in
the RVLM and SAP. Whether the differential cardiovas-
cular responses to E2β activation is gender dependent or
may result from the different amounts of estrogen dis-
tributed in the RVLM caused by different routes of E2β
administration, however, await further delineation.
Both ERα and ERβ are distributed in the RVLM neu-
rons [20,28]. Similar to our previous report [17], at the
receptor level, we found that activation of ERβ in the
Figure 5 Effects of PI3K inhibitor, Akt inhibitor or AdPTEN on the ERβ agonist-induced vasodepressive responses. Time-course of the
changes in MSAP and total power density of vasomotor components (0–0.8 Hz) of SAP spectrum in anaesthetized rats that received
microinjection bilaterally into the RVLM (at time 0) of aCSF, or DPN (2 pmol) given together with LY294002 (LY, 5 pmol), Akt inhibitor (Akt I, 250
pmol) or 5 % DMSO (A), or with additional treatment with AdPTEN (5 × 108 pfu) or AdGFP (5 × 108 pfu), administered into the bilateral RVLM
7 days before DPN (2 pmol) microinjection (B). (C) Representative Western blots (insets) or densitometric analysis of the amount of PTEN protein
relative to basal PTEN protein levels (control), detected from the RVLM 3, 7 or 14 days after animals received microinjection bilaterally into the
RVLM of AdPTEN (5 × 108 pfu) or AdGFP (5 × 108 pfu). (D) Representative photomicrographs showing the distribution of PTEN-immunoreactivity
(arrows) in RVLM on 7 days after animals received bilateral microinjection into the RVLM of aCSF (control), AdPTEN (5 × 108 pfu) or AdGFP (5 × 108
pfu). Calibration bar: 100 μm in low magnification and 50 μm in high magnification of inset. Values are presented as the mean± SEM; n = 6-7
animals per experimental group. *P< 0.05 versus aCSF or control group and #P< 0.05 versus DPN+DMSO or AdGFP+DPN group in the post hoc
Scheffé multiple-range test. NA, nucleus ambiguus; RVLM, rostral ventrolateral medulla.
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Figure 6 Microinjection sites of E2β and DPN in the RVLM. Diagrammatic representations of two rostral-caudal levels of the RVLM (dotted
line areas) with reference to the lambda illustrating the location of sites where bilateral microinjection of E2β (○, 1 pmol) and DPN (●, 2 pmol)
elicited significant inhibitory or minimal effects (■, non-RVLM microinjection sites) on the MSAP and power density of vasomotor components of
SAP spectrum. Numbers on right side indicate distance from the lambda. For the purpose of clarity, approximately 10 % of the total
microinjection sites are included and are presented on both side of the diagram. ION, inferior olivary nucleus; NA, nucleus ambiguous; NTS,
nucleus tractus solitarii; RVLM, rostral ventrolateral medulla; V, nucleus of the spinal trigeminal nerve; py, pyramidal tract.
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effect of estrogen. E2β and the ERβ-selective agonist
DPN, but not the ERα-selective agonist PPT, induced
vasodepressive effects that were almost completely antag-
onized by the nonselective ER antagonist, ICI 182780, or
the ERβ-selective antagonist, R,R-THC. We also found
that blockade of ERβ mRNA expression with a bilateral
microinjection into the RVLM of the ERβ ASON signifi-
cantly attenuated the vasodepressive effects induced by
DPN. ERα ASON treatment, on the other hand, did not
cause a significant change in DPN-induced vasodepres-
sive effects. Together, these findings suggest that ERβ
plays a predominant role in mediating the vasodepressive
effects of estrogen in the RVLM. In support of this sug-
gestion, estrogen-induced rapid inhibition of voltage-
gated Ca++ currents was mediated predominantly by ERβ
in whole-cell patch clamp recordings from the isolated
RVLM neurons [28]. Moreover, the phenotypes observed
for ERβ knockout mice confirm that ERβ is necessary for
the regulation of vascular function and blood pressure
[35]. Examined under electron microscopic level, ERβ-immunoreactivity in the RVLM neurons is more com-
monly found in somata and dendrites, particularly on
plasma membranes, endomembranes and mitochondria
[28], raising therefore a possibility that these primarily
extranuclear ERβ in the RVLM are involved in the rapid,
nongenomic vasodepressor effects of estrogen. In accord-
ance with these cellular observations, we found that both
E2β and ERβ agonist caused rapid and short-term vaso-
depressor responses that occurred approximately 30 min
and sustained for more than 3–4 hours postinjection. A
lack of effect on the observed short-term vasodepressive
responses by AMD further indicates this process does
not require the classical nuclear effects of estrogen
[20,28]. Moreover, these short-term responses were al-
most completely inhibited by co-microinjection with the
ER antagonist, ICI 182780, or the ERβ-selective antagon-
ist, R,R-THC, suggesting that E2β-dependent short-term
vasodepressor responses may be mediated via the rapid
nongenomic activation of ERβ. Minimal alterations in
basal SAP, HR or sympathetic neurogenic vasomotor tone
following application of ERβ antagonist or ERβ ASON
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stances endogenous estrogen and ERβ activation at the
RVLM are not critical for tonic regulation of cardiovascu-
lar performance in male animals. It is noteworthy that
these cardiovascular regulatory effects of the female ster-
oids are site specific, since application of the same agents
to areas outside the confines of the RVLM where ERs are
sparse or not existed [19,20], did not significantly influ-
ence the baseline hemodynamic parameters.
Another important contribution of this study is the es-
tablishment of an intracellular signaling mechanism of
ERβ-dependent nongenomic cardiovascular actions by
estrogen in the RVLM. Our study provided novel evi-
dence to suggest that the vasodepressive effects after
nontranscriptional activation of ERβ in the RVLM may
involve activation of the intracellular PI3K/Akt signaling
pathway. Recently, rapid, nontranscriptional mechanisms
of signal transduction through activated ERs have been
identified. In response to estrogen, ERs can interact with
the p85 regulatory subunit of PI3K and activates the
PI3K/Akt signaling pathway [5,36]. Furthermore, the
PI3K/Akt signaling pathway has been indicated to play a
crucial role in the cardiovascular protective effects of es-
trogen [5-7]. In the present study, the specific PI3K in-
hibitor or Akt inhibitor effectively decreased the
vasodepressive effects induced by ERβ activation. How-
ever, because application of LY294002 or Akt inhibitor
did not completely abolish the ERβ-mediated cardiovas-
cular responses, alternative signaling pathways such as
extracellular signal-regulated kinase/mitogen-activated
protein kinases, tyrosine kinases or transmembrane G-
protein-coupled receptor GPR30 [5,37] in mediating the
ERβ-dependent nongenomic cardiovascular actions can-
not be ruled out.
It is well established that PTEN is a dual phosphatase
that was originally identified as a tumor suppressor pro-
tein and plays a major negative regulator in the PI3K/Akt
signaling pathway [38,39]. Therefore, we overexpressed
the PTEN transgene by the recombinant AdPTEN to
downregulate PI3K activity in the RVLM. In consistent to
the findings reported previously [40], AdPTEN transfec-
tion increased PTEN expression and the distribution of
PTEN-positive cells in the RVLM. The same treatment
also resulted in a significant reversal of the ERβ-mediated
vasodepressive effects similar to that evoked by PI3K and
Akt inhibitors. Together, these observations strongly sup-
port the PI3K/Akt signaling pathway in the E2β-induced
vasodepressive effects in the RVLM. We reported previ-
ously that nitric oxide (NO) participates in the ERβ-
mediated vasodepressive responses in the RVLM [17].
Whether there is a nontranscriptional crosstalk between
ERβ, PI3K/Akt signaling pathway and NO production in
the RVLM to contribute to central regulation of cardio-
vascular functions, however, remains to be clarified.Moreover, the renin-angiotensin system in RVLM also
plays an active role in central regulation of cardiovascular
function and pathogenesis of hypertension [41]. In view
that estrogen levels can selectively affect the expression
and subcellular distribution of the angiotensin type 1
receptors within RVLM neurons [42], and that PI3K/Akt
signaling pathways is involved in angiotensin 1-7-induced
protection against cardiac hypertrophy [43], interactions
between ERs and renin-angiotensin system at RVLM in
central cardiovascular regulation also warrant further
investigation.
Conclusions
In conclusion, our results demonstrate for the first time
that the ERβ-mediated hypotension and reduction in
sympathetic vasomotor tone are dependent on the non-
transcriptional activation of intracellular PI3K/Akt sig-
naling pathway in the RVLM. This finding further
expands the current mechanistic views on estrogen-
replaced cardiovascular protection in postmenopausal
females. In view of a growing incidence of hypertension
in the postmenopausal female, elucidation of these intra-
cellular signaling cascades may therefore provide new in-
formation to link estrogen deficiency with hypertension
and other cardiovascular diseases.
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